Abstract: FR-PO1145
Burden of Proteinuria in Patients with Chronic Kidney Diseases: Insights from the iCaReMe Global Registry
Session Information
- CKD: Screening, Diagnosis, Serum and Urine Biomarkers, and Scoring Indices
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Pollock, Carol A., University of Sydney, Sydney, New South Wales, Australia
- Arici, Mustafa, Hacettepe University Faculty of Medicine, Ankara, Turkey
- Khunti, Kamlesh, Diabetes Research Centre, University of Leicester, Leicester, United Kingdom
- Huang, Chien-Ning, Chung Shan Medical University Hospital, Taichung, Taiwan
- Silva-Tinoco, Ruben, Clinic Specialised in Diabetes Management, Mexico City, Mexico
- El Sayed, Adel, Sohag Faculty of Medicine, Sohag, Egypt
- Farouk, Hisham, AstraZeneca International, Dubai, United Arab Emirates
- Juarez Comboni, Sonia, AstraZeneca International, Dubai, United Arab Emirates
- Vasnawala, Hardik, AstraZeneca International, Dubai, United Arab Emirates
- Hadaoui, Ahmed, AstraZeneca International, Dubai, United Arab Emirates
Background
Chronic kidney disease (CKD) is a growing global health issue, leading to kidney failure, increased morbidity, mortality, and financial strain on healthcare systems. Proteinuria, especially at UACR > 700 mg/g, indicates higher cardiorenal risk, however, data on the management of proteinuric CKD are limited. The iCaReMe Registry offers insights on its global prevalence and management.
Methods
The iCaReMe Registry (NCT03549754) is a multinational, prospective study examining management and care quality of CKD, heart failure, hypertension and type 2 diabetes (T2DM). Analyses included patients with CKD and available UACR from 28 countries (Feb 2018 - Apr 2024). Patients’ demographics, clinical characteristics, and medication use were described overall, and stratified by UACR levels (>700 mg/g, 300-700 mg/g, <300 mg/g).
Results
The study included 2,247 participants (mean age 59.1 years; 50.7% male). The mean UACR was 693 mg/g and mean eGFR was 46 ml/min/1.73m2. 25.4% had UACR > 700 mg/g, 15.4% had 300-700 mg/g, and 59.2% had <300 mg/g. Patients with UACR>700 mg/g, compared to those with UACR<300 mg/g, were younger (55.6 vs 60.5 years), had lower eGFR (36.2 vs 51.5 mL/min/1.73m2), and a lower occurrence of T2DM (54.2 vs 63.6%) (Table 1). While use of ACEi/ARB/ARNi was somewhat higher in the UACR >700 mg/g group (57.7 vs 53.7%), SGLT2is were less frequently used (16.8% vs 29.7%).
Conclusion
Proteinuric CKD poses a significant clinical burden, with 1 out of 4 patients showing UACR > 700 mg/g but suboptimal use of guideline-directed medical therapy. The findings highlight the need for targeted interventions to optimize therapy and improve outcomes in these high-risk patients with CKD.
Funding
- Commercial Support – AstraZeneca Study Sponsor